SEC Form 4 · accession 0001179110-15-010052
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew L Sherman
Officer — EVP & Chief Medical Officer
Period of report
Jun 18, 2015
Accepted (ET)
Jun 19, 2015 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2015 | M | 4,000 | $0.48 | A | 36,004 | D | |
| Common Stock | Jun 18, 2015 | M | 1,600 | $5.08 | A | 37,604 | D | |
| Common StockF2 | Jun 18, 2015 | S | 5,600 | $31.57 | D | 32,004 | D | |
| Common StockF3 | Jun 18, 2015 | S | 1,000 | $31.57 | D | 13,100 | I | By GRAT |
| Common Stock | Jun 18, 2015 | S | 400 | $31.07 | D | 12,700 | I | By GRAT |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF4 | $0.48 | Jun 18, 2015 | M | 4,000 | D | — | May 31, 2016 | Common Stock | 4,000 | 8,000 | D |
| Option to Purchase Common StockF5 | $5.08 | Jun 18, 2015 | M | 1,600 | D | — | Mar 27, 2018 | Common Stock | 1,600 | 22,296 | D |
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.25 to $31.78, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.37 to $31.78, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- F4The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter.
- F5The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.